Short Interest in Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Increases By 50.5%

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) was the target of a large increase in short interest in May. As of May 31st, there was short interest totalling 14,600 shares, an increase of 50.5% from the May 15th total of 9,700 shares. Based on an average daily volume of 15,300 shares, the short-interest ratio is presently 1.0 days. Currently, 0.4% of the shares of the company are sold short.

Protagenic Therapeutics Stock Up 11.1 %

Shares of NASDAQ:PTIX traded up $0.10 during trading on Friday, hitting $1.03. 8,665 shares of the stock traded hands, compared to its average volume of 24,654. The company has a fifty day moving average price of $1.36 and a two-hundred day moving average price of $1.14. Protagenic Therapeutics has a 52-week low of $0.68 and a 52-week high of $2.22. The company has a market cap of $4.57 million, a price-to-earnings ratio of -0.90 and a beta of 0.31.

Protagenic Therapeutics (NASDAQ:PTIX) last released its quarterly earnings data on Monday, April 1st. The company reported ($0.38) earnings per share for the quarter.

Protagenic Therapeutics Company Profile

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.